Health CarePharmaceuticals & Biotechnology
  • Price (JPY)2,756.00
  • Today's Change-3.00 / -0.11%
  • Shares traded1.17m
  • 1 Year change28.42%
  • Beta0.6823
Data delayed at least 20 minutes, as of Feb 19 2020 06:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Kyowa Kirin Co., Ltd., formerly Kyowa Hakko Kirin Co., Ltd. is a Japan-based company principally engaged in the manufacture and sale of medical drugs. The Company operates through two business segments. Pharmaceuticals segment conducts research, development, manufacture and sale of pharmaceuticals and other products. Bio-chemicals segment is involved in the research, development, manufacture and sale of pharmaceuticals and industrial raw materials mainly for amino acid and nucleic acid related substances, as well as healthcare products.

  • Revenue in JPY (TTM)305.82bn
  • Net income in JPY37.68bn
  • Incorporated1949
  • Employees7.24k
  • Location
    Kyowa Kirin Co LtdOtemachi Financial City Grand Cube1-9-2, Ote-machiCHIYODA-KU 100-0004JapanJPN
  • Phone+81 352057200
  • Fax+81 352057182
  • Websitehttps://www.kyowakirin.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
SAWAI PHARMACEUTICAL CO., LTD.186.61bn19.89bn305.05bn3.13k15.241.458.091.63453.98453.984,259.124,781.590.49011.612.5759,600,770.005.346.827.289.1240.9841.0810.9011.631.43130.700.250229.349.6815.4638.239.717.816.47
JCR Pharmaceuticals Co Ltd25.71bn3.65bn333.94bn632.0087.4210.0588.0612.99117.82117.82829.121,024.780.60340.82243.3140,678,800.008.596.6510.767.9969.4765.6314.2412.601.92--0.214530.6812.468.0821.0123.44-17.9716.47
ROHTO PHARMACEUTICAL CO., LTD.187.01bn11.49bn395.01bn6.36k33.312.7821.912.11100.41100.411,636.291,203.560.91922.314.2129,426,590.005.665.118.007.5060.0459.376.165.661.5718.570.023526.036.895.005.491.840.61255.02
Hisamitsu Pharmaceutical Co Inc139.91bn21.30bn464.15bn2.79k21.101.7917.653.32258.31258.311,694.813,047.020.45472.843.7850,111,750.006.986.768.007.8363.4763.1215.3412.714.60--0.006536.08-3.41-0.97850.4446-2.10-2.743.34
Alfresa Holdings Corporation2.70tn35.19bn514.69bn12.08k13.170.988210.980.1906166.23166.2312,758.282,216.201.9215.414.10223,639,600.002.512.647.157.767.517.351.311.301.02--0.002824.241.441.0617.1710.28-8.1410.07
Medipal Holdings Corp3.24tn34.72bn542.11bn13.87k14.800.93359.240.1672149.78149.7813,969.922,375.051.9016.714.41233,836,200.002.582.527.517.587.247.181.361.250.9985--0.104722.861.131.54-1.216.16-5.6610.56
Peptidream Inc6.23bn1.67bn626.55bn104.00376.7636.86286.81100.4913.2713.2749.17135.650.36635.938.3059,949,590.009.8315.2510.2917.1273.0273.9726.8437.8111.35----0.0012.2954.5318.6279.5321.67--
Nippon Shinyaku Co., Ltd.115.81bn15.49bn652.64bn1.95k40.404.4234.515.64229.98229.981,719.422,101.450.69722.392.3859,359,300.009.347.4510.808.7954.6352.4213.3911.123.85--0.0028.2113.088.4425.8623.172.9124.93
Sumitomo Dainippon Pharma Co Ltd469.41bn52.64bn693.54bn6.14k13.161.3310.051.48132.49132.491,181.521,308.660.48261.763.7776,451,630.005.414.628.286.1774.0775.0511.218.230.5621--0.367525.64-1.623.45-9.0219.37-9.749.24
Santen Pharmaceutical Co Ltd243.14bn28.88bn787.33bn4.07k27.392.6017.923.2471.9071.90605.65757.030.61092.972.9359,696,
ONO PHARMACEUTICAL CO., LTD.290.74bn60.24bn1.34tn3.56k21.312.2318.164.60118.94118.94572.631,136.990.45122.403.4581,782,280.009.386.8710.677.7372.9073.3020.7918.012.67--0.015354.0210.2315.042.5020.4318.154.56
Kyowa Kirin Co Ltd305.82bn37.68bn1.49tn7.24k39.482.1826.384.8769.88124.63567.281,263.160.40071.283.16--4.945.275.555.9673.9766.2612.3211.574.59--0.026644.1312.64-1.71-23.4718.83-9.3110.93
Eisai Co., Ltd661.65bn96.66bn2.60tn10.68k26.023.9020.253.93337.23337.232,308.552,249.070.6372.563.6561,934,480.009.305.1013.076.5574.3266.3214.609.091.57--0.145584.887.131.4122.2610.630.17320.00
Data as of Feb 19 2020. Currency figures normalised to Kyowa Kirin Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

11.08%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 30 Sep 201917.51m3.24%
Nikko Asset Management Co., Ltd.as of 10 Jan 20207.54m1.40%
Daiwa Asset Management Co. Ltd.as of 31 Jan 20207.33m1.36%
The Vanguard Group, Inc.as of 31 Dec 20196.90m1.28%
Norges Bank Investment Managementas of 31 Dec 20184.32m0.80%
BlackRock Fund Advisorsas of 06 Feb 20204.24m0.78%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 03 Dec 20193.78m0.70%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 14 Feb 20203.14m0.58%
Massachusetts Financial Services Co.as of 31 Dec 20193.09m0.57%
T. Rowe Price International Ltd. (Japan)as of 31 Dec 20191.97m0.37%
More ▼
Data from 31 Dec 2018 - 31 Dec 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.